UPL Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/oqfhbmgqgi97zt5p9lvzamm2.pdf

Key Takeaways


The Price-Volume Equation

Mike Frank: "Our volume growth will no longer be in the double-digit range. It will likely be kind of in the mid-single digits. But likewise, the pricing headwinds that we've experienced in the first half will largely dissipate."

Margin Bridge & the H2 Inflection Bet

Anand Vora: "We knew that when we started this financial year, we had only about 6 crore of high-cost inventory left. The rest of the inventory was all fresh... because of both these factors, we don't expect this year that $392 million hit or a similar amount of hit is to come by."

Regional & Portfolio Dynamics

RegionTrendCommentary
Latin America▬ Near flatBrazil volumes up 30%+ on fungicides but price erosion in Perito, Feroce, Sperto offset gains; Argentina hurt by shift to closer-to-use-season purchasing.
North America▲ StrongUp ~16% on normalized base after last year's returns and price adjustments; good in-season insecticide and fungicide demand.
Europe▲ StrongUp ~18% led by fungicides; NPP BioSolutions up ~25% on strong volume growth.
India (UPL SAS)▲ StrongRevenue up 20% YoY; contribution margins jumped from 17.1% to 30% on new molecule launches and product mix; EBITDA up 592%.
Rest of World▼ SoftDown 2%; volume growth in Africa moderated by declines in Southeast Asia and Japan.
Advanta Seeds▲ SteadyRevenue up 4% on price and FX despite flat volume; margin-accretive growth in grain sorghum and corn; contribution margins improved 117 bps.

Brazil: Stabilization with Residual Risk


Balance Sheet & Capital Allocation


Strategic Optionality

Mike Frank: "Obviously, with the President-elect Trump coming in on a mandate of trying to make supply chains more resilient and less in dependence on China, I think that would bode well for UPL. Obviously, as an India-based manufacturer, we're prepared to continue to grow our business if the opportunity presents itself in North America."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth4% to 8% YoYFY25
EBITDA growthOver 50% YoY absolute improvementFY25
Operational free cash flow$300 million to $400 million, used to repay debtFY25
Capex~INR1,800 croresFY25
H2 margin normalizationContribution margins return to normalized range on fresh inventory and operating leverageH2 FY25
Volume growthMid-single digits in H2; 5% or less in FY26H2 FY25 / FY26
Price assumptionRelatively flat prices out of China; prices at the bottomPlanning scenario, no timeline for increase
FactoringSelective factoring toward $1 billion outstandingBy end FY25
Net debt-to-EBITDABelow 2x with rights proceedsPost-rights issue completion

Key Metrics

MetricQ2 FY25
Revenue₹11,090 cr, up 9% YoY; volume growth 16%, price decline 7%
Contribution₹4,180 cr, up 3% YoY
Contribution margin37.7%, down 220 bps YoY due to price drops and regional mix
SG&A₹2,604 cr, up 5% YoY; nearly flat YoY excluding ECL provision increase
EBITDA₹1,576 cr, flat YoY
EBITDA margin14.2%, improved 160 bps QoQ from 12.6% in Q1
Adjusted PAT (excl. exceptionals, associates, minority interest)Loss of ₹443 cr, vs loss of ₹189 cr in Q2 FY24
FX losses₹375 cr, higher by ₹146 cr YoY
Net working capital₹14,829 cr (123 days of sales), down from ₹20,116 cr (149 days) in H1 FY24, a reduction of 26 days
Net debt₹27,531 cr (USD 3.285 bn), down ₹3,165 cr from ₹30,697 cr (USD 3.696 bn) in H1 FY24
Gross debt reductionUS$286 mn in H1
Net debt reductionUS$411 mn in H1
UPL Corp revenue growth4% YoY
UPL Corp contribution margin compression~150 bps YoY
NPP BioSolutions revenue growth10% YoY
Differentiated and sustainable segment share of H1 revenue~37%
Latin America revenueNear flat YoY; Brazil volumes grew over 30%
North America revenue growth~16% YoY
Europe revenue growth~18% YoY; NPP BioSolutions up ~25%
Rest of world revenue growth-2% YoY
New product revenue target for FY25$85 mn
India Crop Protection (UPL SAS) revenue₹1,013 cr, up 20% YoY
UPL SAS EBITDA₹203 cr, up 592% YoY; EBITDA margin back to 20%
Advanta Seeds revenue growth4% YoY, driven equally by price and FX
Advanta contribution margin improvement117 bps YoY
FY25 revenue growth guidance4% to 8% YoY
FY25 EBITDA growth guidance50% YoY
FY25 free cash flow guidance₹30 cr to ₹40 cr, to be used for debt repayment
FY25 capex guidance~₹1,800 cr; ₹700 cr spent in H1
Rights issue size$400 mn, revised from up to $500 mn
Average cost of debt~7%, vs ~6.25% in Q2 FY24
Net debt-to-EBITDA target (ex-rights, ex-Advanta monetization)~2–2.2x by March 2025; below 2x with rights proceeds
High-cost inventory remainingLess than $20–30 mn out of ~$1 bn total inventory
Last year's special rebates and inventory mark-to-market hit~$392 mn
Last year EBITDA$666 mn; adding $392 mn takes to ~$1 bn, slightly above 50% growth target